axd121

Adam P. Dicker, MD, PhD, FASTRO, FASCO

Contact Dr. Dicker

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6700
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Use of a cancer registry to evaluate patient-reported outcomes of immune checkpoint inhibitors
  2. Virtual Connectivity During Quarantine: The Role of Social Media for Radiation Oncology During COVID-19
  3. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
  4. AI-based prognostic imaging biomarkers for precision neuro-oncology: The ReSPOND consortium
  5. A newly developed OSL dosimeter based on beryllium oxide: BeO:Na,Dy,Er
  6. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma
  7. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
  8. A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer
  9. Innovations in research and clinical care using patient-generated health data
  10. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
  11. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer
  12. Utilizing digital health to collect electronic patient-reported outcomes in prostate cancer: Single-arm pilot trial
  13. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group
  14. A Pilot Study of Radiation Therapy in Combination with Pembrolizumab in Patients with Metastatic Renal Cell Cancer
  15. Provider engagement in radiation oncology data science: workshop report
  16. The role of lineage plasticity in prostate cancer therapy resistance
  17. Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment Naïve primary prostate cancer
  18. Big Data From Small Devices: The Future of Smartphones in Oncology
  19. Clinical outcome assessments toolbox for radiopharmaceuticals
  20. Tumor-Derived Extracellular Vesicles Require β1 Integrins to Promote Anchorage-Independent Growth
  21. Artificial intelligence in oncology: Current applications and future directions
  22. PARP-1 regulates DNA repair factor availability
  23. Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus
  24. Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer
  25. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial